Reduction of fluconazole susceptibility of Candida albicans in APECED patients due to long-term use of ketoconazole and miconazole

Scandinavian Journal of Infectious Diseases

Volumn 40, Issue 11-12, 2008, Pages 904-907

  Rautemaa, Riina ^a,b   Richardson, Malcolm ^a,b   Pfaller, Michael ^c   Perheentupa, Jaakko ^d   Saxén, Harri ^d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF IOWA   (United States)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; KETOCONAZOLE; MICONAZOLE; PYRROLE DERIVATIVE;

ADOLESCENT; ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; CANDIDA ALBICANS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG USE; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; MEDICAL RECORD; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SCHOOL CHILD;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; KETOCONAZOLE; MICONAZOLE; POLYENDOCRINOPATHIES, AUTOIMMUNE;

EID: 57049101467     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540802275853     Document Type: Article

References (18)

1. Perheentupa, J. (2006) Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab, 91, pp. 2843-2850.
2. Collins, SM, Dominguez, M., Ilmarinen, T., Costigan, C. and Irvine, AD. (2006) Dermatological manifestations of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. Br J Dermatol, 154, pp. 1088-1093.
3. Rautemaa, R., Hietanen, J., Niissalo, S., Pirinen, S. and Perheentupa, J. (2007) Oral and oesophageal squamous cell carcinoma: A complication or component of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED, APS-I). Oral Oncol, 43, pp. 607-613.
4. Sitheeque, MA and Samaranayake, LP. (2003) Chronic hyperplastic candidosis/candidiasis (candidal leukoplakia). Crit Rev Oral Biol Med, 14, pp. 253-267.
5. Fan-Havard, P., Capano, D., Smith, SM, Mangia, A. and Eng, RH. (1991) Development of resistance in candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother, 35, pp. 2302-2305.
6. Heald, AE, Cox, GM, Schell, WA, Bartlett, JA and Perfect, JR. (1996) Oropharyngeal yeast flora and fluconazole resistance in HIV infected patients receiving long-term continuous versus intermittent fluconazole therapy. AIDS, 10, pp. 263-268.
7. Rex, JH, Rinaldi, MG and Pfaller, MA. (1995) Resistance of Candida species to fluconazole. Antimicrob Agents Chemother, 39, pp. 1-8.
8. Goldman, M., Cloud, GA, Smedema, M., LeMonte, A., Connolly, P. McKinsey, DS et al. (2000) Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses study group. Antimicrob Agents Chemother, 44, pp. 1585-1587.
9. Smith, KJ, Warnock, DW, Kennedy, CT, Johnson, EM, Hopwood, V., van Cutsem, J. and van den Bossche, H. (1986) Azole resistance in Candida albicans. J Med Vet Mycol, 24, pp. 133-144.
10. Rautemaa, R., Richardson, M., Pfaller, M., Koukila-Kahkola, P., Perheentupa, J. and Saxen, H. (2007) Decreased susceptibility of Candida albicans to azole antifungals: A complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. J Antimicrob Chemother, 60, pp. 889-892.
11. Johnson, EM, Richardson, MD and Warnock, DW. (1984) In vitro resistance to imidazole antifungals in Candida albicans. J Antimicrob Chemother, 13, pp. 547-558.
12. Johnson, EM and Warnock, DW. (1995) Azole drug resistance in yeasts. J Antimicrob Chemother, 36, pp. 751-755.
13. Fothergill, AW. (2006) Miconazole: A historical perspective. Expert Rev Anti Infect Ther, 4, pp. 171-175.
14. Akins, RA. (2005) An update on antifungal targets and mechanisms of resistance in Candida albicans. Med Mycol, 43, pp. 285-318.
15. Sanglard, D. and Odds, FC. (2002) Resistance of Candida species to antifungal agents: Molecular mechanisms and clinical consequences. Lancet Infect Dis, 2, pp. 73-85.
16. Kamai, Y., Maebashi, K., Kudoh, M., Makimura, K., Naka, W., Uchida, K. and Yamaguchi, H. (2004) Characterization of mechanisms of fluconazole resistance in a Candida albicans isolate from a Japanese patient with chronic mucocutaneous candidiasis. Microbiol Immunol, 48, pp. 937-943.
17. Lamb, DC, Kelly, DE, Manning, NJ and Kelly, SL. (1997) Reduced intracellular accumulation of azole antifungal results in resistance in Candida albicans isolate NCPF 3363. FEMS Microbiol Lett, 147, pp. 189-193.
18. Marichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P. Luyten, W. et al. (1999) Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology, 145, pp. 2701-2713.